Compare C3.ai Inc (AI) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
C3.ai Inc vs Zimmer Biomet Holdings Inc — how do they compare? C3.ai Inc trades at $10.26 (market cap $1.65B), while Zimmer Biomet Holdings Inc trades at $96.08 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 11.2× C3.ai Inc's market cap, and Zimmer Biomet Holdings Inc pays a 0.99% dividend while C3.ai Inc pays none. Which is the better fit depends on your goals.
| AI | ZBH | |
|---|---|---|
Market Cap | $1.65B | $18.55B |
Sector | Technology | Health |
52-Week High | $19.66 | $107.71 |
52-Week Low | $7.76 | $79.58 |
Enterprise Value | $1.08B | $25.61B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
C3.ai (AI) trades at $10.25, down 1.44% on the day, with mixed technical signals showing bullish moving averages but overbought RSI readings. The company maintains strong revenue growth, reaching $389 million in 2025, but continues to report significant losses with a -74.21% net margin. Recent positive developments include being named a Leader in AI Platforms by Forrester Research.
While technical indicators suggest short-term bullish momentum, fundamental challenges persist with consistent negative profitability. The stock faces execution risk in achieving profitability despite growing enterprise AI adoption. Analyst consensus remains cautious with only 21% buy ratings and a $10.20 price target slightly below current levels.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About C3.ai Inc
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
